Craniopharyngioma

Craniopharyngiomas, also known as Rathke’s pouch tumour or craniopharyngeal duct tumours, are rare tumours that develop in the sellar and parasellar regions of the brain. It is classed as a type of central nervous system (CNS), which is made up of the brain and spinal cord.

The sellar and parasellar regions of the brain are complex, and hold and support many important structures in the brain. The sellar region of the brain is located in the centre of the cranial base (bottom portion of the skull), and is made up of the pituitary gland, a primary endocrine gland of the body, and the sella tunica, a bony pouch that the pituitary gland sits in. The parasellar region holds cavernous sinuses, suprasellar cistern, hypothalamus, and ventral inferior third valve.

In most cases, craniopharyngiomas are benign and carry a good prognosis. In very rare cases, the tumours can undergo a transformation and become malignant.

Craniopharyngiomas tend to be diagnosed in children between the ages of 5-14, or in adults over 50 years old. They are generally diagnosed equally between the sexes, and can develop in anyone at any age.

Types of Craniopharyngiomas

There are two primary types of craniopharyngioma, which are categorised by the types of cells they develop from.

Adamantinomatous Craniopharyngioma

Adamantinomatous craniopharyngiomas (ACP) are primarily found in children, and generally develop from cells in the craniopharyngeal duct. The craniopharyngeal duct is a bony channel that connects the bottom of the sella tunica to the nasopharynx (a structure in the upper most portion of the throat, behind the nose). ACPs can be solid or cystic (growth filled with liquid). They are often classified as grade I (or low grade) tumours, as they develop slowly and rarely spread. While they may have a high recurrence rate, they generally carry a good prognosis.

Papillary Craniopharyngioma

Papillary craniopharyngiomas (PCP) are a less common subtype of craniopharyngiomas that are more common in adults. They generally develop from cells in the anterior portion (or front) of the pituitary gland. PCPs can be solid or cystic, and are often classified as grade I tumours. While they may have a high recurrence rate, they generally carry a good prognosis.

Malignant Craniopharyngioma

In very rare cases, a benign craniopharyngiomas can undergo a malignant transformation and become cancerous. It is not clear what causes this transformation, but a potential link to previous radiation therapy has been identified. Malignant craniopharyngiomas are not well understood, but are thought to develop more rapidly and are more likely to metastasise. The prognosis for malignant craniopharyngiomas may not be as good as benign craniopharyngiomas.

Treatment

When cancers are detected, they are staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you. However, brain cancers are rarely staged, as they rarely spread to other parts of the body. Instead, they are generally graded from grades I-III.

Because of how rare craniopharyngiomas are, there is currently no standard grading system for this disease. Instead of grading, your doctor will recommend a treatment plan based on the following factors:

  • Cancer location.
  • Whether or not the cancer has metastasised.
  • Your age.
  • General health.
  • Your treatment preferences.

Your doctor may also recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment options for craniopharyngiomas may include:

  • Surgery to remove as much of the tumour as possible, potentially including a craniotomy.
  • Radiation therapy.
  • Chemotherapy.
  • Hormone replacement therapy.
  • Targeted therapy.
  • Clinical trials.
  • Palliative care.

Risk factors

Because of how rare craniopharyngiomas are, there has been limited research done into the risk factors of this disease. However, a potential link to previous radiation therapy has been identified, but more research would be required to confirm this.

Symptoms

The symptoms of a craniopharyngiomas are often related to the pressure that the tumour is putting on the brain, pituitary gland, and nearby nerves. They usually occur when the tumour reaches a certain size. General symptoms may include:

  • Nausea and/or vomiting.
  • Confusion.
  • Mood swings.
  • Behavioural changes.
  • Fatigue.
  • Balance difficulties.
  • Polydipsia.
  • Polyuria.
  • Vision changes, potentially including:
    • Blurred vision.
    • Diplopia.
    • Loss of peripheral vision.
    • Blindness.
  • Persistent headaches.

Craniopharyngiomas can result in decreased hormone production which may cause additional symptoms:

  • Delayed growth in children as a result of growth hormone (GH) deficiency.
  • Follicle stimulating hormone (FSH) or luteinizing hormone (LH) deficiency, which may result in:
    • Delayed puberty.
    • Amenorrhea.
    • Precocious puberty (rare).
  • Adrenocorticotropic hormone (ACTH) deficiency, which may cause:
    • Unexplainable weight loss/loss of appetite.
    • Muscle weakness.
    • Hypotension.
    • Diarrhoea.
    • Hypoglycaemia.
    • Dilutional hyponatraemia.
  • Thyroid stimulating hormone (TSH) deficiency, which may cause:
    • Fatigue.
    • Lethargy.
    • Menstrual changes.
    • Forgetfulness.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have a craniopharyngioma, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Neurological examination.
  • Endocrine studies.
  • Imaging tests, potentially including:
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.